Evidence map›Paper›PMID 31390061›Full record

ArticleCancer2019

Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Ingrid Lorese Tablazon, Lauren E Howard, Amanda M De Hoedt, William J Aronson, Christopher J Kane, Christopher L Amling, Matthew R Cooperberg, Martha K Terris, Stephen J Freedland, Stephen B Williams

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Ingrid Lorese TablazonDivision of Urology, Durham Veterans Affairs Medical Center, Durham, North Carolina.
Lauren E HowardBiostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina.
Amanda M De HoedtDivision of Urology, Durham Veterans Affairs Medical Center, Durham, North Carolina.
William J AronsonDepartment of Urology, University of California at Los Angeles Medical Center, Los Angeles, California.
Christopher J KaneDivision of Urology, University of California at San Diego Health System, San Diego, California.
Christopher L AmlingDivision of Urology, Department of Surgery, Oregon Health and Science University, Portland, Oregon.
Matthew R CooperbergDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco Medical Center, San Francisco, California.
Martha K TerrisSection of Urology, Department of Surgery, Medical College of Georgia, Augusta University, Augusta, Georgia.
Stephen J FreedlandDivision of Urology, Durham Veterans Affairs Medical Center, Durham, North Carolina.ORCID 0000-0002-8104-6419
Stephen B WilliamsDivision of Urology, Department of Surgery, The University of Texas Medical Branch, Galveston, Texas.ORCID 0000-0002-2683-2185
Durham VA Medical Center · USAugusta University · USCedars-Sinai Medical Center · USDuke Cancer InstituteOregon Health & Science University · USSan Francisco VA Medical Center · USThe University of Texas Medical Branch at Galveston · USUC San Diego Health System · USWadsworth Center · US

Funding

Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate CancerR01CA231219 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARONSON, WILLIAM J, COHEN, PINCHAS · 2018 to 2022
$2.1M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
Bayer PharmaceuticalsNational Institutes of Health/National Cancer Institute R01CA231219NCI NIH HHS K24 CA160653NCI NIH HHS R01 CA231219
6 · The paper itself

Abstract

backgroundAlthough skeletal-related events (SREs) are linked with a reduced quality of life and worse outcomes, to the authors' knowledge the factors that predict SREs are minimally understood. The objective of the current study was to identify predictors of SREs and all-cause mortality among men with metastatic castration-resistant prostate cancer (mCRPC).

methodsData were collected on 837 men with bone mCRPC at 8 Veterans Affairs medical centers within the Shared Equal Access Regional Cancer Hospital (SEARCH) database from 2000 through 2017. Patients were followed to assess development of SREs (pathological fracture, radiotherapy to bone, spinal cord compression, or surgery to bone). Cox proportional hazards models were used to evaluate predictors of SREs and mortality.

resultsOf the 837 men with bone mCRPC, 287 developed a SRE and 740 men died (median follow-up, 26 months). Bone pain was found to be the strongest predictor of SREs (hazard ratio [HR], 2.96; 95% CI, 2.25-3.89). A shorter time from CRPC to the development of metastasis (HR, 0.92; 95% CI, 0.85-0.99), shorter progression to CRPC (HR, 0.94; 95% CI, 0.91-0.98), and visceral metastasis at the time of diagnosis of bone metastasis (HR, 1.91; 95% CI, 1.18-3.09) were associated with an increased risk of SREs. Ten or more bone metastases (HR, 2.17; 95% CI, 1.72-2.74), undergoing radical prostatectomy (HR, 0.73; 95% CI, 0.61-0.89), shorter progression to CRPC (HR, 0.97; 95% CI, 0.94-0.99), older age (HR, 1.03; 95% CI, 1.02-1.04), higher prostate-specific antigen level at the time of diagnosis of metastasis (HR, 1.21; 95% CI, 1.14-1.28), bone pain (HR, 1.44; 95% CI, 1.23-1.70), and visceral metastasis (HR, 1.72; 95% CI, 1.23-2.39) were associated with an increased mortality risk.

conclusionsAmong men with bone mCRPC, bone pain was found to be the strongest predictor of SREs and the number of bone metastases was a strong predictor of mortality. If validated, these factors potentially may be used for risk stratification and for SRE prevention strategies.

Indexed as

AgedAged, 80 and overBiopsyBone DiseasesBone NeoplasmsCause of DeathDisease SusceptibilityFollow-Up StudiesHumansKaplan-Meier EstimateMaleMortalityNeoplasm StagingPrognosisProstatic Neoplasms, Castration-Resistantbonemetastasispredictorsprostate cancerShared Equal Access Regional Cancer Hospital (SEARCH)skeletal events

Identifiers

PMID31390061
PMCPMC6819222
OpenAlexW2965368164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.